According to Gram Research analysis, a heart protein called Cryab loses a protective chemical modification called lactylation in people with diabetes, which causes a second protein called Hspa1b to break down and allows harmful cell signals to damage the heart. This 2026 study in mice and heart cells suggests that future treatments targeting this lactylation modification could help prevent diabetic heart disease, though human studies are still needed.
Scientists discovered that a protein called Cryab protects the heart from damage caused by diabetes, but this protection weakens when the protein loses a special chemical modification called lactylation. Using mouse models and heart cells, researchers found that when Cryab loses this modification, it can no longer protect another protein called Hspa1b, which then fails to block harmful signals that damage the heart. This discovery, published in Diabetes in 2026, suggests that new treatments targeting this protein modification could help prevent heart problems in people with diabetes.
Key Statistics
A 2026 research article in Diabetes found that Cryab protein loses its lactylation modification in diabetic mouse hearts and cultured heart cells exposed to high glucose and fat, compared to healthy controls.
Mice with a genetic mutation preventing Cryab lactylation showed worsened heart function, increased scarring, excessive heart growth, and increased cell death compared to normal mice, demonstrating the protective importance of this modification.
When Cryab loses its lactylation modification, the protective protein Hspa1b degrades and disappears, allowing the harmful MAPK signaling pathway to become overactive and damage the heart in diabetic conditions.
The Quick Take
- What they studied: How a heart protein called Cryab protects against diabetes-related heart damage, and what happens when this protein loses a chemical modification called lactylation
- Who participated: Two groups of mice with diabetes (one naturally diabetic, one made diabetic through diet and injection), plus heart cells grown in the laboratory exposed to high sugar and fat
- Key finding: When Cryab loses its lactylation modification, it cannot properly support another protective protein called Hspa1b, allowing harmful cell signals to activate and damage the heart
- What it means for you: This research identifies a new target for future diabetes heart disease treatments, though human studies are still needed to confirm these findings work the same way in people
The Research Details
Researchers used two different mouse models of diabetes to study how a heart protein called Cryab works. The first group of mice naturally develop diabetes, while the second group was given a high-fat diet combined with a chemical injection to trigger diabetes. The team examined heart tissue from these mice and also grew heart cells in dishes, exposing them to high levels of glucose and fat to mimic diabetic conditions.
The researchers focused on a specific chemical modification called lactylation that attaches to the Cryab protein. They compared how much lactylation was present in healthy hearts versus diabetic hearts, and then used genetic techniques to create mutations that prevented lactylation from occurring. This allowed them to see what happens when this protective modification is missing.
The study also tracked how Cryab interacts with another protein called Hspa1b, and how this interaction affects harmful cell signaling pathways called MAPK. By measuring protein levels, cell death, and heart function in both mice and cultured cells, the researchers built a complete picture of how this protective mechanism works.
Using both living mice and laboratory-grown cells allowed researchers to confirm their findings in multiple systems. The two different mouse models of diabetes helped ensure the results weren’t specific to just one type of diabetes. By studying the specific genetic mutation, scientists could prove that lactylation is truly responsible for the protective effect, not just something that happens alongside it.
This study was published in Diabetes, a peer-reviewed scientific journal, which means other experts reviewed the work before publication. The researchers used established mouse models of diabetes that are widely recognized in the scientific community. However, the study was conducted in mice and laboratory cells, not humans, so results may not directly translate to people. The specific sample sizes for mouse groups were not provided in the abstract, which limits our ability to assess statistical power.
What the Results Show
The main discovery was that Cryab protein loses its lactylation modification in diabetic hearts. When researchers examined heart tissue from diabetic mice and from heart cells exposed to high glucose and fat, they found significantly reduced lactylation compared to healthy controls. Importantly, the total amount of Cryab protein stayed the same, meaning the problem was specifically the loss of this chemical modification, not the loss of the protein itself.
When scientists created a genetic mutation that prevented lactylation from occurring at a specific location (K90R), the results were dramatic. Mice with this mutation showed worse heart function, including problems with both how forcefully the heart pumped (systolic dysfunction) and how well it relaxed (diastolic dysfunction). The hearts also showed increased scarring (fibrosis), excessive growth (hypertrophy), and increased cell death (apoptosis).
The mechanism behind this protection involves a second protein called Hspa1b. When Cryab has proper lactylation, it stabilizes and protects Hspa1b. But when lactylation is lost, Hspa1b degrades and disappears. Without Hspa1b, harmful cell signals called the MAPK pathway become overactive, leading to the heart damage seen in diabetes.
The research revealed that the Cryab-Hspa1b interaction is lactylation-dependent, meaning it only works properly when Cryab has this chemical modification. The MAPK signaling pathway, which was already known to be harmful in diabetic hearts, appears to be the final step in this chain of events. By blocking this pathway through the Cryab-Hspa1b interaction, the heart can resist some of the damage from diabetes. The findings were consistent across both mouse models and laboratory cell studies, suggesting this mechanism is robust.
Previous research has shown that lactylation is important for heart energy metabolism and that the MAPK pathway contributes to diabetic heart disease. This study builds on that knowledge by identifying a specific protein (Cryab) and a specific modification site (K90) that controls this protective mechanism. The discovery that lactylation can regulate protein-protein interactions in the heart is relatively novel and opens new avenues for understanding how chemical modifications protect against disease.
The study was conducted entirely in mice and laboratory cells, not in humans, so we cannot yet confirm these findings apply to people with diabetes. The abstract does not specify how many mice were used in each group, making it difficult to assess whether the sample sizes were adequate. The research focused on one specific protein modification and one signaling pathway, so there may be other important mechanisms in diabetic heart disease that were not examined. Additionally, the study did not test any potential treatments targeting this pathway, so we do not yet know if modifying lactylation could actually help patients.
The Bottom Line
This research is still in the early stages and has not yet led to treatments for people. However, it suggests that future drugs targeting lactylation of Cryab or stabilization of Hspa1b could potentially help prevent heart damage in people with diabetes. Anyone with diabetes should continue following their doctor’s current recommendations for heart health, including blood sugar control, blood pressure management, and regular exercise. This research should not change current medical practice until human studies confirm these findings.
People with diabetes who are concerned about heart health should be aware of this emerging research, though it is not yet ready for clinical use. Researchers studying diabetic heart disease and protein modifications will find this work particularly relevant. Healthcare providers treating diabetes may eventually use this knowledge to develop new preventive strategies. People without diabetes do not need to take action based on this research at this time.
Since this research has not yet been tested in humans, there is no realistic timeline for seeing benefits in patients. Typically, promising laboratory findings like these require 5 to 10 years of additional research, including animal studies and human clinical trials, before new treatments become available. Patients should not expect any new treatments based on this work for several years at minimum.
Frequently Asked Questions
Can this research help treat diabetes heart disease in people right now?
Not yet. This research was conducted in mice and laboratory cells, not humans. Scientists must conduct additional animal studies and human clinical trials before any new treatments based on this discovery become available to patients, which typically takes several years.
What is lactylation and why does it matter for the heart?
Lactylation is a chemical modification that attaches to proteins and affects how they function. In this study, lactylation on the Cryab protein allows it to protect another protein called Hspa1b, which then blocks harmful signals that damage the diabetic heart.
Should people with diabetes change their treatment based on this study?
No. This research is preliminary and has not been tested in humans. People with diabetes should continue following their doctor’s current recommendations for blood sugar control, blood pressure management, and heart health until new treatments are developed and proven safe and effective.
How does this discovery relate to current diabetes medications?
This research identifies a new biological mechanism that contributes to diabetic heart disease, separate from how current diabetes medications work. Future drugs might target this lactylation pathway in addition to existing treatments, but this is still years away from clinical use.
Why did researchers use mice instead of testing humans directly?
Mouse studies allow researchers to control variables precisely, use genetic mutations safely, and examine heart tissue directly in ways that would be unethical in humans. Successful mouse studies provide the foundation for eventual human clinical trials.
Want to Apply This Research?
- Users with diabetes could track heart health markers including resting heart rate, blood pressure readings, and exercise duration to monitor cardiovascular wellness while waiting for future treatments based on this research
- Implement or maintain daily aerobic exercise (30 minutes most days) and consistent blood sugar monitoring, as these remain the most evidence-based ways to protect the heart in diabetes until new lactylation-targeting treatments become available
- Establish a baseline of current heart health metrics (blood pressure, resting heart rate, exercise capacity) and track these monthly to detect any changes, while staying informed about clinical trials testing new diabetes heart disease treatments
This research was conducted in mice and laboratory cells, not in humans. The findings have not yet been tested in clinical trials and should not be used to guide personal medical decisions. People with diabetes should continue following their healthcare provider’s recommendations for managing blood sugar, blood pressure, and heart health. Anyone considering changes to their diabetes treatment should consult with their doctor before making any modifications. This article is for educational purposes only and does not constitute medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.